Related Experiment Video
Updated: May 3, 2026

13:26
Induction and Monitoring of Active Delayed Type Hypersensitivity DTH in Rats
Published on: July 19, 2007
17.2K
Relative refractory state for late cutaneous allergic responses
The Journal of Allergy and Clinical Immunology
|October 1, 1977
Summary
A repeat exposure to allergens temporarily reduces the late cutaneous allergic response (LCAR), suggesting a natural control mechanism. This refractory state is nonspecific and lasts for weeks, impacting future allergic reactions.
Area of Science:
- Immunology
- Dermatology
- Allergy Research
Background:
- The late cutaneous allergic response (LCAR) typically follows the immediate wheal-and-flare reaction in intense allergic responses.
- Understanding the regulation of LCAR is crucial for managing allergic diseases.
Purpose of the Study:
- To investigate the existence and characteristics of a refractory state for LCAR after an initial allergic reaction.
- To determine the immunological specificity and duration of this refractory state.
Main Methods:
- Cutaneous allergic reactions were induced using anti-IgE or allergen injections.
- Repeat injections were performed at initial reaction sites and control sites after one week.
- Early (wheal-and-flare) and late (LCAR) responses were measured and compared.
Main Results:
- The early response (wheal diameter) remained consistent upon repeat injection.
- The LCAR was significantly reduced at previously reacted sites compared to control sites.
- This refractory state was immunologically nonspecific and lasted for 2-3 weeks.
Conclusions:
- A local, antigen-nonspecific refractory state for LCAR exists following an initial allergic reaction.
- This refractory period may serve as an endogenous inhibitory mechanism to control allergic responses in humans.
- Further research could explore therapeutic implications of this finding in allergic conditions.
Related Concept Videos
Allergic Reactions
26.4K
Overview
26.4K
Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Hypersensitivities
7.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.3K
Drug Toxicity: Allergic Reactions
209
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
209
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
359
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
359
Hypersensitivity Reactions: Immune-Complex Reactions
269
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
269

